Merck KGaA (FRA:MRK) received a €98.00 ($116.67) price objective from stock analysts at Nord/LB in a research note issued on Friday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Nord/LB’s target price would indicate a potential upside of 10.27% from the company’s current price.

A number of other research analysts have also weighed in on MRK. Goldman Sachs Group set a €105.00 ($125.00) target price on Merck KGaA and gave the company a “neutral” rating in a report on Thursday, August 17th. DZ Bank restated a “neutral” rating on shares of Merck KGaA in a report on Thursday, August 17th. Berenberg Bank set a €109.00 ($129.76) price target on Merck KGaA and gave the company a “neutral” rating in a research report on Friday, August 18th. Independent Research set a €105.00 ($125.00) price target on Merck KGaA and gave the company a “neutral” rating in a research report on Monday, August 28th. Finally, equinet set a €112.00 ($133.33) price target on Merck KGaA and gave the company a “buy” rating in a research report on Thursday, August 31st. Twelve investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Merck KGaA presently has an average rating of “Hold” and a consensus target price of €107.81 ($128.34).

Merck KGaA (FRA:MRK) traded up €0.97 ($1.15) during mid-day trading on Friday, hitting €88.87 ($105.80). The stock had a trading volume of 348,819 shares. Merck KGaA has a 52 week low of €87.33 ($103.96) and a 52 week high of €115.00 ($136.90).

TRADEMARK VIOLATION NOTICE: “Nord/LB Analysts Give Merck KGaA (MRK) a €98.00 Price Target” was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/12/08/nordlb-analysts-give-merck-kgaa-mrk-a-98-00-price-target.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.